You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTelmisartan
Accession NumberDB00966  (APRD01247)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Structure
Thumb
Synonyms
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
BIBR 277
Micardis
Telmisartan
External Identifiers
  • BIBR 277
  • BIBR 277SE
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Telmisartantablet40 mgoralActavis Pharma Company2012-10-19Not applicableCanada
Act Telmisartantablet80 mgoralActavis Pharma Company2012-10-19Not applicableCanada
Auro-telmisartantablet40 mgoralAuro Pharma Inc2016-04-08Not applicableCanada
Auro-telmisartantablet80 mgoralAuro Pharma Inc2016-04-08Not applicableCanada
KinzalmonoTablet40 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOral useBayer Pharma Ag1998-12-16Not applicableEu
Mar-telmisartantablet40 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-telmisartantablet80 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardistablet40 mg/1oralPhysicians Total Care, Inc.2005-01-19Not applicableUs
MicardisTablet20 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardistablet40 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
Micardistablet80 mg/1oralPhysicians Total Care, Inc.2002-03-25Not applicableUs
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardistablet80 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
Micardistablet20 mg/1oralPhysicians Total Care, Inc.2010-11-02Not applicableUs
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardistablet80 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-15Not applicableUs
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardistablet20 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
MicardisTablet20 mgOral useBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardis 40mg Tabtablet40 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1999-09-01Not applicableCanada
Micardis 80mg Tabtablet80 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1999-09-01Not applicableCanada
Mylan-telmisartantablet40 mgoralMylan Pharmaceuticals Ulc2012-01-10Not applicableCanada
Mylan-telmisartantablet80 mgoralMylan Pharmaceuticals Ulc2012-01-10Not applicableCanada
Ntp-telmisartantablet80 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-telmisartantablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-telmisartantablet40 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-telmisartantablet80 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-telmisartantablet40 mgoralPharmascience Inc2012-08-28Not applicableCanada
PMS-telmisartantablet80 mgoralPharmascience Inc2012-08-28Not applicableCanada
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOral useBayer Pharma Ag1998-12-11Not applicableEu
Ran-telmisartantablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-14Not applicableCanada
Ran-telmisartantablet80 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-14Not applicableCanada
Sandoz Telmisartantablet80 mgoralSandoz Canada Incorporated2012-01-04Not applicableCanada
Sandoz Telmisartantablet40 mgoralSandoz Canada Incorporated2012-01-04Not applicableCanada
Septa-telmisartantablet40 mgoralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Septa-telmisartantablet80 mgoralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Telmisartantablet20 mg/1oralRoxane Laboratories, Inc.2014-01-08Not applicableUs
Telmisartantablet80 mgoralPharmascience Inc2015-02-12Not applicableCanada
Telmisartantablet40 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Telmisartantablet80 mgoralSanis Health Inc2012-07-20Not applicableCanada
Telmisartantablet40 mgoralPharmascience Inc2015-02-12Not applicableCanada
Telmisartantablet40 mg/1oralRoxane Laboratories, Inc.2014-01-08Not applicableUs
Telmisartantablet80 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Telmisartantablet40 mgoralSivem Pharmaceuticals Ulc2012-07-26Not applicableCanada
Telmisartantablet80 mg/1oralRoxane Laboratories, Inc.2014-01-08Not applicableUs
Telmisartantablet80 mgoralSivem Pharmaceuticals Ulc2012-07-26Not applicableCanada
Telmisartantablet40 mgoralSanis Health Inc2012-07-20Not applicableCanada
Telmisartan Tabletstablet40 mgoralAccord Healthcare Inc2014-03-12Not applicableCanada
Telmisartan Tabletstablet80 mgoralAccord Healthcare Inc2014-03-12Not applicableCanada
Teva-telmisartantablet40 mgoralTeva Canada Limited2012-01-09Not applicableCanada
Teva-telmisartantablet80 mgoralTeva Canada Limited2012-01-09Not applicableCanada
Torrent-telmisartantablet40 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-telmisartantablet80 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-telmisartantablet40 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-telmisartantablet80 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Zinda-telmisartantablet40 mgoralZinda Pharma LimitedNot applicableNot applicableCanada
Zinda-telmisartantablet80 mgoralZinda Pharma LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-telmisartantablet80 mgoralApotex Inc2014-07-18Not applicableCanada
Apo-telmisartantablet40 mgoralApotex Inc2014-07-18Not applicableCanada
Telmisartantablet20 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
Telmisartantablet40 mg/1oralQualitest Pharmaceuticals2013-03-06Not applicableUs
Telmisartantablet20 mg/1oralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
Telmisartantablet20 mg/1oralMedsource Pharmaceuticals2014-08-27Not applicableUs
Telmisartantablet80 mg/1oralSandoz Inc2015-02-06Not applicableUs
Telmisartantablet40 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
Telmisartantablet20 mg/1oralAurobindo Pharma Limited2015-09-03Not applicableUs
Telmisartantablet40 mg/1oralActavis Pharma, Inc.2014-01-08Not applicableUs
Telmisartantablet80 mg/1oralQualitest Pharmaceuticals2013-03-06Not applicableUs
Telmisartantablet40 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
Telmisartantablet40 mg/1oralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
Telmisartantablet20 mg/1oralCadila Healthcare Limited2014-08-27Not applicableUs
Telmisartantablet80 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
Telmisartantablet20 mg/1oralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
Telmisartantablet40 mg/1oralAurobindo Pharma Limited2015-09-03Not applicableUs
Telmisartantablet80 mg/1oralActavis Pharma, Inc.2014-01-08Not applicableUs
Telmisartantablet20 mg/1oralSandoz Inc2015-02-06Not applicableUs
Telmisartantablet80 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
Telmisartantablet80 mg/1oralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
Telmisartantablet40 mg/1oralCadila Healthcare Limited2014-08-27Not applicableUs
Telmisartantablet40 mg/1oralAvera Mc Kennan Hospital2015-04-15Not applicableUs
Telmisartantablet40 mg/1oralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
Telmisartantablet80 mg/1oralAurobindo Pharma Limited2015-09-03Not applicableUs
Telmisartantablet20 mg/1oralQualitest Pharmaceuticals2013-03-06Not applicableUs
Telmisartantablet40 mg/1oralSandoz Inc2015-02-06Not applicableUs
Telmisartantablet20 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
Telmisartantablet20 mg/1oralActavis Pharma, Inc.2014-01-08Not applicableUs
Telmisartantablet80 mg/1oralCadila Healthcare Limited2014-08-27Not applicableUs
Telmisartantablet80 mg/1oralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOral useTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgTeva B.V.2010-01-26Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOral useTeva B.V.2011-10-03Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOral useKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PritorNot Available
Brand mixtures
NameLabellerIngredients
Ach-telmisartan HctzAccord Healthcare Inc
Act Telmisartan/hctActavis Pharma Company
Apo-telmisartan/hctzApotex Inc
Auro-telmisartan HctzAuro Pharma Inc
Micardis HctBoehringer Ingelheim Pharmaceuticals, Inc.
Micardis PlusBoehringer Ingelheim (Canada) Ltd Ltee
Mylan-telmisartan HctzMylan Pharmaceuticals Ulc
Ntp-telmisartan HctzTeva Canada Limited
Pendo-telmisartan-hctzPendopharm Division Of De Pharmascience Inc
PMS-telmisartan-hctzPharmascience Inc
Ran-telmisartan HctzRanbaxy Pharmaceuticals Canada Inc.
Sandoz Telmisartan HctSandoz Canada Incorporated
Telmisartan and AmlodipineMylan Pharmaceuticals Inc.
Telmisartan and HydrochlorothiazideRoxane Laboratories, Inc.
Telmisartan and Hydrochlorothiazide 40 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/25 mgAlembic Pharmaceuticals Limited
Telmisartan and HydrochlorthiazideTorrent Pharmaceuticals Limited
Telmisartan HctzSivem Pharmaceuticals Ulc
Telmisartan-hctzPro Doc Limitee
Telmisartan/hctzSanis Health Inc
Teva-telmisartan HctzTeva Canada Limited
Torrent-telmisartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
TwynstaBoehringer Ingelheim Pharmaceuticals, Inc.
Van-telmisartan-hctzVanc Pharmaceuticals Inc
Zinda-telmisartan/ HctzZinda Pharma Limited
SaltsNot Available
Categories
UNIIU5SYW473RQ
CAS number144701-48-4
WeightAverage: 514.6169
Monoisotopic: 514.236876224
Chemical FormulaC33H30N4O2
InChI KeyInChIKey=RMMXLENWKUUMAY-UHFFFAOYSA-N
InChI
InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
IUPAC Name
2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid
SMILES
CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBiphenyls and derivatives
Direct ParentBiphenyls and derivatives
Alternative Parents
Substituents
  • Biphenyl
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • N-substituted imidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
PharmacodynamicsTelmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. It has the highest affinity for the AT1 receptor among commercially available ARBS and has minimal affinity for the AT2 receptor. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects, as PPARγ is a nuclear receptor that regulates specific gene transcription, and whose target genes are involved in the regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.
Mechanism of actionTelmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPARγ activators.
Related Articles
AbsorptionAbsolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).
Volume of distribution
  • 500 L
Protein bindingHighly bound to plasma proteins (>99.5%), mainly albumin and a1-acid glycoprotein. Binding is not dose-dependent.
Metabolism

Minimally metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.

Route of eliminationFollowing either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Half lifeBi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
Clearance
  • >800 mL/min
ToxicityIntravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Telmisartan Action PathwayDrug actionSMP00164
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8794
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6061
P-glycoprotein inhibitor INon-inhibitor0.5261
P-glycoprotein inhibitor IIInhibitor0.8653
Renal organic cation transporterNon-inhibitor0.6047
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateInhibitor0.5699
CYP450 2C9 inhibitorNon-inhibitor0.5481
CYP450 2D6 inhibitorNon-inhibitor0.7796
CYP450 2C19 inhibitorNon-inhibitor0.5509
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.601
Ames testNon AMES toxic0.6432
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.8075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9166
hERG inhibition (predictor II)Non-inhibitor0.7114
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral use20 mg
TabletOral use40 mg
TabletOral use80 mg
Tabletoral40 mg
Tabletoral80 mg
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tabletoral
Tablet20 mg
Tablet40 mg
Tablet80 mg
Tablet, multilayeroral
Prices
Unit descriptionCostUnit
Micardis 30 40 mg tablet Box110.11USD box
Micardis HCT 30 40-12.5 mg tablet Box106.34USD box
Micardis HCT 30 80-12.5 mg tablet Box106.18USD box
Micardis 30 80 mg tablet Box103.92USD box
Micardis HCT 30 80-25 mg tablet Box100.48USD box
Micardis 30 20 mg tablet Box99.7USD box
Micardis 20 mg tablet3.29USD tablet
Micardis hct 40-12.5 mg tablet3.29USD tablet
Micardis hct 80-12.5 mg tablet3.29USD tablet
Micardis hct 80-25 mg tablet3.29USD tablet
Micardis 40 mg tablet2.24USD tablet
Micardis 80 mg tablet2.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2060624 No1999-12-212012-02-04Canada
US5591762 No1994-01-072014-01-07Us
US6358986 No2000-01-102020-01-10Us
US7998953 No2000-06-062020-06-06Us
US8003679 No2002-10-062022-10-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point261-263 °CNot Available
water solubilityPractically insolubleNot Available
logP7.7Not Available
Caco2 permeability-4.82ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0035 mg/mLALOGPS
logP6.66ALOGPS
logP6.04ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.65ChemAxon
pKa (Strongest Basic)6.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.94 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity164.49 m3·mol-1ChemAxon
Polarizability58.61 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference
  1. Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. Pubmed
General References
  1. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835 ]
  2. Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501. [PubMed:12462282 ]
  3. Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. doi: 10.3762/bjoc.6.25. [PubMed:20502601 ]
  4. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797 ]
External Links
ATC CodesC09DB04C09DA07C09CA07
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (47.4 KB)
MSDSDownload (101 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Telmisartan.
AcebutololTelmisartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Telmisartan.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Telmisartan.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Telmisartan.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Telmisartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Telmisartan.
AliskirenTelmisartan may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Telmisartan.
AlprenololAlprenolol may increase the hypotensive activities of Telmisartan.
AmbrisentanTelmisartan may increase the hypotensive activities of Ambrisentan.
AmifostineTelmisartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Telmisartan.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Telmisartan.
AmlodipineAmlodipine may increase the hypotensive activities of Telmisartan.
AmobarbitalAmobarbital may increase the hypotensive activities of Telmisartan.
Amyl NitriteThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Telmisartan.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Telmisartan.
ApremilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apremilast.
ArdeparinArdeparin may increase the hyperkalemic activities of Telmisartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Telmisartan.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Telmisartan.
AtenololAtenolol may increase the hypotensive activities of Telmisartan.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Telmisartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Telmisartan.
BemiparinBemiparin may increase the hyperkalemic activities of Telmisartan.
BenazeprilBenazepril may increase the hypotensive activities of Telmisartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Telmisartan.
BenmoxinBenmoxin may increase the hypotensive activities of Telmisartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benoxaprofen.
BepridilTelmisartan may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Telmisartan.
BetaxololBetaxolol may increase the hypotensive activities of Telmisartan.
BethanidineBethanidine may increase the hypotensive activities of Telmisartan.
BimatoprostBimatoprost may increase the hypotensive activities of Telmisartan.
BisoprololBisoprolol may increase the hypotensive activities of Telmisartan.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Telmisartan.
BosentanBosentan may increase the hypotensive activities of Telmisartan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Telmisartan.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.
BretyliumTelmisartan may increase the hypotensive activities of Bretylium.
BrimonidineTelmisartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Telmisartan.
BromfenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.
BupranololTelmisartan may increase the hypotensive activities of Bupranolol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Telmisartan.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Telmisartan.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Telmisartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Telmisartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Telmisartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Telmisartan.
CaptoprilTelmisartan may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Telmisartan.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Telmisartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Telmisartan.
CarprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Telmisartan.
CarvedilolTelmisartan may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.
CeliprololTelmisartan may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Telmisartan.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Telmisartan.
CertoparinCertoparin may increase the hyperkalemic activities of Telmisartan.
ChloroquineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Telmisartan.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Telmisartan.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Telmisartan.
CilazaprilTelmisartan may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Telmisartan.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Telmisartan.
CiprofloxacinTelmisartan may increase the arrhythmogenic activities of Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Telmisartan.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Telmisartan.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Telmisartan.
ClevidipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Telmisartan.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Telmisartan.
ClonidineClonidine may increase the hypotensive activities of Telmisartan.
ClonixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Telmisartan.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Telmisartan.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Telmisartan.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Telmisartan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Telmisartan.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Telmisartan.
CryptenamineCryptenamine may increase the hypotensive activities of Telmisartan.
CyclosporineTelmisartan may increase the hyperkalemic activities of Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Telmisartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Telmisartan is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Telmisartan.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Telmisartan.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Telmisartan.
DalteparinDalteparin may increase the hyperkalemic activities of Telmisartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Telmisartan.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Telmisartan.
DebrisoquinTelmisartan may increase the hypotensive activities of Debrisoquin.
DeserpidineTelmisartan may increase the hypotensive activities of Deserpidine.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Telmisartan.
DiazoxideDiazoxide may increase the hypotensive activities of Telmisartan.
DiclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Telmisartan.
DiflunisalThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Telmisartan.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Telmisartan.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Telmisartan.
DiltiazemDiltiazem may increase the hypotensive activities of Telmisartan.
DinutuximabThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Telmisartan.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Telmisartan.
DorzolamideDorzolamide may increase the hypotensive activities of Telmisartan.
DoxazosinDoxazosin may increase the hypotensive activities of Telmisartan.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Telmisartan.
DrospirenoneTelmisartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam.
DuloxetineTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Telmisartan.
EfonidipineTelmisartan may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Telmisartan.
EmpagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Telmisartan.
EnalaprilatTelmisartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Telmisartan.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Telmisartan.
EpirizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Telmisartan.
EplerenoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Eplerenone.
EpoprostenolTelmisartan may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Telmisartan.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Telmisartan.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Telmisartan.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Telmisartan.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Telmisartan.
EstriolThe serum concentration of Estriol can be increased when it is combined with Telmisartan.
EstroneThe serum concentration of Estrone can be increased when it is combined with Telmisartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.
EtanerceptThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Telmisartan.
EtodolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Telmisartan.
EtoricoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.
exisulindThe risk or severity of adverse effects can be increased when Telmisartan is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Telmisartan.
FelodipineTelmisartan may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Telmisartan.
FenoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenoprofen.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Telmisartan.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Telmisartan.
FloctafenineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Telmisartan.
FosinoprilFosinopril may increase the hypotensive activities of Telmisartan.
FurazolidoneFurazolidone may increase the hypotensive activities of Telmisartan.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Telmisartan.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Telmisartan.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Telmisartan.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Telmisartan.
GuanabenzGuanabenz may increase the hypotensive activities of Telmisartan.
GuanadrelGuanadrel may increase the hypotensive activities of Telmisartan.
GuanethidineTelmisartan may increase the hypotensive activities of Guanethidine.
GuanfacineTelmisartan may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Telmisartan.
HeparinHeparin may increase the hyperkalemic activities of Telmisartan.
HexamethoniumTelmisartan may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Telmisartan.
HMPL-004The risk or severity of adverse effects can be increased when Telmisartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Telmisartan.
HydralazineTelmisartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTelmisartan may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Telmisartan.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Telmisartan.
IbuprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Telmisartan is combined with Icatibant.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Telmisartan.
IloprostIloprost may increase the hypotensive activities of Telmisartan.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Telmisartan.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Telmisartan.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Telmisartan.
IndapamideIndapamide may increase the hypotensive activities of Telmisartan.
IndenololTelmisartan may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Telmisartan.
IndomethacinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indoprofen.
IndoraminTelmisartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Telmisartan.
IproniazidIproniazid may increase the hypotensive activities of Telmisartan.
IrbesartanTelmisartan may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Telmisartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Telmisartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Telmisartan.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Telmisartan.
KebuzoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Telmisartan.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Telmisartan.
KetoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Telmisartan.
LacidipineTelmisartan may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Telmisartan.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Telmisartan.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Telmisartan.
LatanoprostLatanoprost may increase the hypotensive activities of Telmisartan.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Telmisartan.
LeflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Telmisartan.
LercanidipineLercanidipine may increase the hypotensive activities of Telmisartan.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Telmisartan.
LevobunololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levobunolol.
LevodopaTelmisartan may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Telmisartan.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Telmisartan.
LisinoprilLisinopril may increase the hypotensive activities of Telmisartan.
LithiumThe serum concentration of Lithium can be increased when it is combined with Telmisartan.
LofexidineTelmisartan may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Telmisartan.
LornoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Telmisartan.
LoxoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lumiracoxib.
MacitentanTelmisartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.
ManidipineTelmisartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.
MasoprocolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Telmisartan.
MecamylamineMecamylamine may increase the hypotensive activities of Telmisartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Telmisartan.
MethohexitalMethohexital may increase the hypotensive activities of Telmisartan.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Telmisartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.
MethyldopaTelmisartan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Telmisartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Telmisartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Telmisartan.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.
MetipranololTelmisartan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Telmisartan.
MetoprololMetoprolol may increase the hypotensive activities of Telmisartan.
MibefradilTelmisartan may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Telmisartan.
MinaprineMinaprine may increase the hypotensive activities of Telmisartan.
MinoxidilMinoxidil may increase the hypotensive activities of Telmisartan.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Telmisartan.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Telmisartan.
MoclobemideMoclobemide may increase the hypotensive activities of Telmisartan.
MoexiprilMoexipril may increase the hypotensive activities of Telmisartan.
MolsidomineMolsidomine may increase the hypotensive activities of Telmisartan.
MorphineThe serum concentration of Morphine can be increased when it is combined with Telmisartan.
MoxonidineTelmisartan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.
NadololTelmisartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Telmisartan.
NaftifineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Telmisartan.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Telmisartan.
NaproxenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Telmisartan is combined with NCX 4016.
NebivololTelmisartan may increase the hypotensive activities of Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Telmisartan.
NepafenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Telmisartan.
NicardipineNicardipine may increase the hypotensive activities of Telmisartan.
NicorandilNicorandil may increase the hypotensive activities of Telmisartan.
NifedipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.
NiguldipineTelmisartan may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Telmisartan.
NilvadipineTelmisartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Telmisartan.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Telmisartan.
NisoldipineNisoldipine may increase the hypotensive activities of Telmisartan.
NitrendipineTelmisartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Telmisartan.
NitroprussideNitroprusside may increase the hypotensive activities of Telmisartan.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Telmisartan.
ObinutuzumabTelmisartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Telmisartan.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Telmisartan.
OlmesartanOlmesartan may increase the hypotensive activities of Telmisartan.
OlopatadineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Telmisartan.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Telmisartan.
OrgoteinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Telmisartan.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Telmisartan.
OxaprozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.
OxprenololTelmisartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Telmisartan.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Telmisartan.
PapaverineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parecoxib.
PargylineTelmisartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Telmisartan.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.
PenbutololTelmisartan may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Telmisartan.
PentoliniumTelmisartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Telmisartan.
PerindoprilPerindopril may increase the hypotensive activities of Telmisartan.
PhenelzinePhenelzine may increase the hypotensive activities of Telmisartan.
PheniprazinePheniprazine may increase the hypotensive activities of Telmisartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Telmisartan.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Telmisartan.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Telmisartan.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Telmisartan.
PhentolaminePhentolamine may increase the hypotensive activities of Telmisartan.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Telmisartan.
PimecrolimusThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.
PinacidilTelmisartan may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Telmisartan.
PirfenidoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Telmisartan.
PiroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Telmisartan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Telmisartan.
PolythiazideTelmisartan may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Telmisartan.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Telmisartan.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Telmisartan.
PrazosinPrazosin may increase the hypotensive activities of Telmisartan.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Telmisartan.
PrimidonePrimidone may increase the hypotensive activities of Telmisartan.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Telmisartan.
PropacetamolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Telmisartan.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Telmisartan.
PTC299The risk or severity of adverse effects can be increased when Telmisartan is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Telmisartan.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Telmisartan.
QuinineQuinine may increase the hypotensive activities of Telmisartan.
QuinineThe serum concentration of Quinine can be increased when it is combined with Telmisartan.
RamiprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.
RamiprilRamipril may increase the hypotensive activities of Telmisartan.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Telmisartan.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Telmisartan.
RasagilineRasagiline may increase the hypotensive activities of Telmisartan.
RemikirenRemikiren may increase the hypotensive activities of Telmisartan.
RescinnamineTelmisartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Telmisartan.
ResveratrolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Telmisartan.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Telmisartan.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Telmisartan.
RiociguatTelmisartan may increase the hypotensive activities of Riociguat.
RisperidoneTelmisartan may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Telmisartan.
RituximabTelmisartan may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Telmisartan.
RofecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rofecoxib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Telmisartan.
SafrazineSafrazine may increase the hypotensive activities of Telmisartan.
SalicylamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.
SaprisartanTelmisartan may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Telmisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Telmisartan.
SelegilineSelegiline may increase the hypotensive activities of Telmisartan.
SelexipagTelmisartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Telmisartan.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Telmisartan.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Telmisartan.
SitaxentanTelmisartan may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Telmisartan.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Telmisartan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Telmisartan.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Telmisartan.
SpiraprilTelmisartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Telmisartan.
SRT501The risk or severity of adverse effects can be increased when Telmisartan is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Telmisartan.
TadalafilTadalafil may increase the antihypertensive activities of Telmisartan.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Telmisartan.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Telmisartan.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Telmisartan.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Telmisartan.
TemocaprilTelmisartan may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.
TenoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Teriflunomide.
TerlipressinTelmisartan may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Telmisartan.
ThiopentalThiopental may increase the hypotensive activities of Telmisartan.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.
TiboloneTelmisartan may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Telmisartan.
TicrynafenTelmisartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Telmisartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Telmisartan.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.
TolazolineTolazoline may increase the hypotensive activities of Telmisartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Telmisartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Telmisartan.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Telmisartan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Telmisartan.
TorasemideTorasemide may increase the hypotensive activities of Telmisartan.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Telmisartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Telmisartan.
TranilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Telmisartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Telmisartan.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Telmisartan.
TravoprostTravoprost may increase the hypotensive activities of Telmisartan.
TreprostinilTreprostinil may increase the hypotensive activities of Telmisartan.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Telmisartan.
TrichlormethiazideTelmisartan may increase the hypotensive activities of Trichlormethiazide.
TrimazosinTelmisartan may increase the hypotensive activities of Trimazosin.
TrimethaphanTelmisartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Telmisartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Telmisartan.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Telmisartan.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Telmisartan.
UnoprostoneTelmisartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Telmisartan.
VardenafilVardenafil may increase the antihypertensive activities of Telmisartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Telmisartan.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Telmisartan.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Telmisartan.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Telmisartan.
XylometazolineTelmisartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Telmisartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Telmisartan.
ZileutonThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Karlberg BE, Lins LE, Hermansson K: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999 Feb;17(2):293-302. [PubMed:10067800 ]
  3. Balt JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA: Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol. 2001 Jul;38(1):141-8. [PubMed:11444497 ]
  4. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T: AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther. 2001 Jul;298(1):62-70. [PubMed:11408526 ]
  5. Strohmenger HU, Lindner KH, Wienen W, Vogt J: Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Resuscitation. 1997 Aug;35(1):61-8. [PubMed:9259062 ]
  6. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004 Oct 22;576(3):492-7. [PubMed:15498586 ]
  7. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835 ]
  8. McClellan KJ, Markham A: Telmisartan. Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6. [PubMed:9878991 ]
  9. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797 ]
  10. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680 ]
  11. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288 ]
  12. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862 ]
  13. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852 ]
  14. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680 ]
  2. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288 ]
  3. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862 ]
  4. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852 ]
  5. Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16. [PubMed:15868121 ]
  6. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961 ]
  7. Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12. [PubMed:16154710 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 02:22